Sugi Predict

Sugi Predict / Compounds / SCHEMBL3209060

SCHEMBL3209060

SCHEMBL3209060

Cc1ccc(NC(=O)Nc2cc(CN3CCN(C(=O)O)CC3)c(F)cc2Cl)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MAPK10 P53779 6/20 0.42
▸ MAPK8 P45983 5/20 0.42
▸ MAPK9 P45984 1/20 0.42
▸ RORC P51449 1/20 0.42
▸ DHODH Q02127 1/20 0.42
▸ GRM5 P41594 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ FAAH O00519 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GPR6 P46095 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ LIMK1 P53667 1/20 0.39
▸ KCNQ3 O43525 1/20 0.39
▸ KCNQ2 O43526 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401732 0.92 NPSR1 (0.43) NPSR1MAPK10MAPK8MAPK9RORC
SCHEMBL3210260 0.92 RORC (0.44) NPSR1MAPK10MAPK8MAPK9RORC
SCHEMBL3215364 0.87 KCNQ3 (0.45) NPSR1MAPK10MAPK8RORCDHODH
SCHEMBL3206500 0.85 NPSR1 (0.48) NPSR1GRM5FAAHSMN1; SMN2NPC1
SCHEMBL3197411 0.84 SMN1; SMN2 (0.50) NPSR1MAPK10MAPK8FAAHSMN1; SMN2
SCHEMBL3211043 0.84 RORC (0.43) NPSR1MAPK10MAPK8RORCDHODH
SCHEMBL401322 0.83 ALDH1A1 (0.45) MAPK10MAPK8MAPK9RORCDHODH
SCHEMBL3198567 0.83 RORC (0.51) NPSR1MAPK10MAPK8RORCDHODH
SCHEMBL3204614 0.82 FAAH (0.45) MAPK10MAPK8FAAHSMN1; SMN2NPC1
SCHEMBL3196731 0.82 RORC (0.50) NPSR1MAPK10MAPK8RORCDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 NPSR1 4262/4885MAPK10 2342/4885MAPK8 3165/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 NPSR1 4682/4885MAPK10 2458/4885MAPK8 3317/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 NPSR1 4567/4885MAPK10 1989/4885MAPK8 2821/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 NPSR1 4682/4885MAPK10 2458/4885MAPK8 3317/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 NPSR1 3300/4885MAPK10 2706/4885MAPK8 3594/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 NPSR1 4682/4885MAPK10 2458/4885MAPK8 3317/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 NPSR1 4780/4885MAPK10 2521/4885MAPK8 3460/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 NPSR1 3300/4885MAPK10 2706/4885MAPK8 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.